



AISLADO CBD



DESTILADO THC



CBD
HIDROSOLUBLE



Blueberries
Medical Corp.

LATIN AMERICAN PRODUCER AND DEVELOPER OF CANNABIS DERIVED INGREDIENTES

Annual General And Special Meeting Of Shareholders
September 29, 2021

Disclaimers

This confidential presentation has been prepared by Blueberries Medical Corp. (“the Company” or “Blueberries”). This presentation and the material contained herein are confidential and are not to be disclosed to the public. This presentation is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities of the Company in any jurisdiction. Such an offer can only be made by prospectus or other authorized offering document. This presentation and materials or fact of their distribution or communication shall not form the basis of, or be relied on in connection with any contract, commitment or investment decision whatsoever in relation thereto. No securities commission or similar authority in Canada or any other jurisdiction has in any way passed upon the adequacy or accuracy of the information contained in this presentation. Readers of this presentation should pay particular attention to the information under the headings “Cautionary Note Regarding Forward-Looking Information” and “Risk Factors”.

By their acceptance of this presentation, recipients agree that they will not transmit, reproduce or make available to any person this presentation or any of the information contained herein. Some information in this presentation describes the Company’s business plan, only including certain assets and relationships held and timing of future events (for example, commencement of operations and the execution dates of material partnership and commercial agreements for the international distribution of the Company’s products).

Cautionary Note Regarding Forward-Looking Information

Certain information set forth in this presentation contains “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian and United States securities legislation (referred to herein as forward-looking statements). Except for statements of historical fact, certain information contained herein constitutes forward-looking statements which includes but is not limited to statements related to activities, events or developments that the Company expects or anticipates will or may occur in the future, statements related to the Company’s business strategy, objectives and goals, and management’s assessment of future plans and operations which are based on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect. Forward-looking statements are often identified by the use of words such as “may”, “will”, “could”, “would”, “anticipate”, “believe”, “expect”, “intend”, “potential”, “estimate”, “budget”, “scheduled”, “plans”, “planned”, “forecasts”, “goals” and similar expressions. Forward-looking statements are based on a number of factors and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. In this presentation, forward-looking statements relate to, among other things, the Company’s strategies and objectives, future expansion plans under consideration, entering into proposed commercial agreements to develop and advance the Company’s business interests, the estimated cost of production for the Company’s products, the expected value of the global medicinal cannabis market, market growth and size, future revenues, targeted EBITDA and profits, proposed use of the Company’s funds, expected timing and receipt of necessary government licensing and approvals, ability to scale the Company’s production model, execution of distribution strategy and forecasts of the number of product lines and sales.

Historical statements should not be taken as a representation that such trends will be replicated in the future. No statement in this presentation is intended to be nor may be construed as a profit forecast. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other

factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among others, include: expected timelines for business acquisition and launches; proposed use of cash on hand for the Company’s capital and other expenditures; generating and finalizing contractual arrangements on terms favorable to the Company or at all; the ability to achieve product milestones in order to satisfy customer demands and deliveries prior to the execution of definitive customer contracts; market acceptance and adoption of the Company’s business plan and the ability to specifically tailor the Company’s platform to meet the demands of prospective customers; the ability to modify, enhance and adjust business plans to meet the demands of current and prospective customers; market growth and size; re-allocation of resources to meet customer demands; Company strategies and objectives; changes to pricing of the Company’s services; forecast of number of product lines and sales; commencement of new operations and plans for expansion; the inability for the Company to execute its corporate strategy as described in this presentation or at all; risks related to partnership or other joint operations; regulatory changes; availability or integration of personnel, materials and equipment; inability to recruit or retain management and key personnel; changes to the composition of the board of directors and management team; capital requirements, operating risks and technological risks associated with the operations or an expansion of the operations of the Company; fluctuations in the currency markets; changes in interest rates; disruption to the credit markets and delays in obtaining financing; inflationary pressures; adverse changes to market, political and general economic conditions or laws, rules and regulations applicable to the Company; regulatory changes or actions that may alter or prohibit operations of companies engaged in cannabis; the Company’s operations and profitability may be adversely affected by competition from other cannabis companies; and factors discussed under the heading “Risk Factors” in this presentation.

Cautionary Note Regarding Future-Oriented Financial Information

To the extent any forward-looking information in this presentation constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out above under the heading “Cautionary Note Regarding Forward Looking Information”. The Company’s actual financial position and results of operations may differ materially from management’s current expectations and, as a result, the Company’s revenue and expenses may differ materially from the revenue and expenses profiles provided in this presentation. Such information is presented for illustrative purposes only and may not be an indication of the Company’s actual financial position or results of operations.

Third Party Information

This presentation includes market and industry data which was obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this presentation, or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation as to the accuracy of such information.

Currency

Unless otherwise indicated, all dollar (“\$”) values herein are in United States dollars.

02 REVENUE STREAMS



Genetics

Sales of cuttings to local licensed producers started in May 2020

Export to Uruguay and Argentina expected in Q4-2021 - **New**



Extraction Services (Tolling)

Processing services for third party producers started in Q4-2020, ramp up in Q2-2021

Extended to Broad Spectrum remediation through third-party in Q3_2021 - **New**



Bulk Oil / Standardized Formulas

Sales of raw material and finished products started in Q1-2021

Ramp up and exports to Peru in Q2-2021



CBD Cosmetics

Sales of CBD Cosmetics

Sales started in Q2-2020



Medical / Finished formulations

Sales and production for Colombia started in August 2021

Sales in Brazil expected in Q4-2021 - **New**

03 PROCESSING & EXTRACTION



03 PROCESSING & EXTRACTION

30,000 sf facility

Initial capacity to process up to 70,000 kg/year of dried flower

GMP Compliant Technology and SOP

TECHNOLOGY

CO2 Extraction

BULK OIL

-Crude Oil

-Standardized formula based on Full Spectrum



04 SCALABLE DESIGN

GMP COMPLIANT DESIGN

Drying and grinding
Diverse CO₂ extraction
lines
Diverse Ethanol extraction
lines
Post extraction area
Blending area



05 EXTRACTION LINE OPERATING

Most Efficient
EU-GMP Compliant
(competitive advantage
against competitors)
Complementary and
compatible to Ethanol
extraction

**Blueberries is the first company
to have an EU-GMP machine
with new stainless-steel
extraction vessels** (Source:
Vitalis Extraction Tech.)





Standardized Extracts from Full Spectrum

Extracted using CO2 methodology, based on Cannabis Flower Sativa

Available:

- 5% CBD : < 0.2% THC
- 10% CBD : < 0.2% THC
- 20% CBD : < 1% THC
- 20% CBD : < 0.2% THC - **New**

Applications:

- Extract Oils/Medical
- Health/Wellness
- Beauty/Cosmetics
- Food Industry
- Veterinary

White Lable Standardized Extracts from Full Spectrum

Contains grape seed oil

Available:

- 5% CBD : < 0.2% THC
- 10% CBD : < 0.2% THC
- 20% CBD : < 1% THC
- 20% CBD : < 0.2% THC - **New**

Applications:

- Extract Oils/Medical
- Health/Wellness
- Beauty/Cosmetics
- Food Industry
- Veterinary

12

Hours of daily light year round

142

Operational cannabis strains (CBD and THC)

60

Kilometers from the Bogota International Airport

21°C

Average temperature with average humidity below 45% for ideal cultivation in greenhouse

70%

of Colombia's cut flower production is from the region in which Blueberries operates



Farm # 1

- * 4 Hectares (442,000 sq. ft.)
- * Nursery, propagation and production center
- * Fully operational

Farm #2

- * 15 Hectares (1,614,585 sq. ft.)
- * Outdoor cultivation
- * Not fully operational yet

08 PROPRIETARY STRAINS

3 COMMERCIAL CANNABIS STRAINS FULLY LICENSED

- * 142 proprietary Colombian cannabis strains with high CBD and THC content 3 of them are now register with the Colombian government
- * Approval of first lot of stabilized cultivars by the Colombian Agricultural Institute (ICA)
- * 1 THC strain fully license for commercial activities



OS MILESTONES & CATALYSTS

2020

ACHIEVED

- * Fully Licensed in Colombia (cultivation, extraction, production & export)
- * CSE, Frankfurt Stock Exchange and OTCQB Listing
- * Premium Cosmetic line approved by INVIMA in Colombia
- * First Lot of Cultivars Approved
- * First commercial crop
- * First Extraction Line Commissioned
- * First Commercial Extraction
- * **Sales Commencement**

2021

A

- * Exports of extracts and standardized formulas
- * Sales ramp up of CBD Cosmetics through partnership
- * Approval of THC genetics and investigation quota (commercial quota estimated at the end of the year)
- * Sales of tolling services (extraction)
- * Manufacturing of standardized formulas with local GMP certified partner
- * Authorization to export cutting and seeds - **New**


10 LEADERSHIP



Facundo Garreton

Chairman and Interim CEO

- * 20+ years of experience
- * Successful entrepreneur in innovation, technology and life sciences
- * Former member of Argentinian Congress
- * Founder of InvertirOnline.com
- * Founder and director of SocialLab and Sistema B
- * Investor and Director of YVY Life Sciences, Pachama.com, VU Security, Untech.bio, Bulltick, GoodPeople, Inipop.com and others.



Guillermo P Rodriguez

Chief Financial Officer

- * 25+ years of financial leadership
- * Former CFO of NEC Argentina, UOL Sinectis, IT Convergence and others.
- * Extensive private market experience
- * Over 12+ of CEO at SETSA, a Real State Co, in Argentina
- * Expertise in high-growth and startup stage organizations across various industries including Technology, Real State and Multimedia Sectors.



Jose Maria Forero

President, Latam Operations

- * 17+ years of sales, marketing and management experience
- * C-level executive and entrepreneur
- * Former Global Head of B2B at Clever Leaves
- * Demonstrated experience in developing, manufacturing, positioning, and distributing products and services
- * Proven track record in highly competitive and regulated industries



11 MANAGEMENT TEAM



Gustavo Gutierrez
Operations Director

- * Pharmaceutical Chemist
- * Biotechnology Master Degree focused on natural products-based drug discovery.
- * Extensive pharmaceutical industry experience
- * Track record in operating vertically integrated Cannabis business
- * Expertise in low risk + high profitable products development in pharmaceutical industry.



Juan Guillermo Latorre
Commercial Director

- * Bachelor's Degree International Relations
- * Master in Operations Management, Supply Chain and Logistics
- * Diploma in Strategic Marketing
- * 10+ years of experience in Sales & Marketing in B2B
- * 10+ years of experience specialty ingredients, food and chemical industry
- * Specialty in value-added solutions of cocoa, lipids, sugar and cannabis



Thomas Rodriguez
Financial Director

- * Bachelor's Degree in Accounting.
- * Master in Business Administration in IAE Business School with focus in leadership and strategic planning.
- * Effective Negotiating Certification from Madero Institute.
- * 10+ years of experience in finance roles in multinational companies (Deloitte & Shell).
- * Extensive manufacturing industry experience.



12 BOARD OF DIRECTORS

Years of Experience

Facundo Garreton

Chairman & Interim CEO



20+

Sebastian Hochbaum

Director



5+

Patricio Villalba

Founding Director



10+

Catherine Lathwell

Director



10+

Joaquin Barbera

Director



20+



Blueberries
Medical Corp.

Jose Forero

LATAM President of Operations

☎ +57 3103458808

✉ jforero@blueberriesmed.com

Guillermo Rodriguez

Chief Financial Officer

☎ +54 91160152227

✉ Grodriguez@blueberriesmed.com

Juan Guillermo Latorre

Commercial Director

☎ +57 3003086000

✉ jlatorre@blueberriesmed.com